Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates

1 day ago 1

Sheryar Siddiq

Tue, February 3, 2026 astatine 5:55 AM CST 2 min read

Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the mid-cap stocks to bargain according to apical investors. On January 20, H.C. Wainwright boosted its terms people for Axsome Therapeutics Inc. (NASDAQ:AXSM) to $260 from $200 and kept a Buy standing connected the biopharma’s shares. The spike comes aft Axsome Therapeutics Inc. (NASDAQ:AXSM) announced interim unaudited fiscal results for the 4th fourth of 2025, with full merchandise gross projected to beryllium astir $196 million.

Axsome Therapeutics Inc. (NASDAQ:AXSM) expects wide merchandise gross to beryllium astir $638.5 cardinal successful fiscal twelvemonth 2025, an betterment of 66% implicit fiscal twelvemonth 2024 and higher than H.C. Wainwright’s prediction of $628.3 million. The company’s superior product, AUVELITY, is projected to bring successful nett income of astir $155.1 cardinal successful Q4 and $507.1 cardinal successful the afloat twelvemonth 2025, acold exceeding the firm’s yearly income estimation of $397 million.

The company’s different products besides performed well, with SUNOSI projected to timepiece successful $36.7 cardinal successful Q4 gross and $124.8 cardinal for the year.

Axsome Therapeutics Inc. (NASDAQ:AXSM) is simply a biopharmaceutical institution that develops and delivers caller therapies for the absorption of cardinal tense system/CNS disorders successful the US.

While we admit the imaginable of AXSM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.